Seattle, WA April 3, 2024 – Pluristyx, a leading provider of tools, technologies, and services for cellular therapies, is pleased to announce the release of its proprietary cryopreservation medium solution, PluriFreeze™. Immediately available in a Research Use Only (RUO) formulation with a Good Manufacturing Practice (GMP) version on the horizon, PluriFreeze™ constitutes a further addition to Pluristyx’s panCELLa™ Platform for iPSC therapeutic development, with broad applicability for other sensitive cell types.
PluriFreeze™ is an innovative solution designed to support cell metabolism and ease pluripotent stem and other energetically active cells to and from the frozen state to enhance post-thaw viability and function. In comparison to other commercially available cryo-media, PluriFreeze™ offers significant benefits for cell therapy development that include an entirely synthetic and Animal-Origin Free (AOF) composition, low viscosity for automation and large-scale cell production, and a companion DMSO-free PluriPrep™ wash solution to enable extended processing times. In addition, PluriFreeze™ is entirely formulated with components Generally Recognized As Safe (GRAS) by the US Federal Food, Drug, and Cosmetic Act to ensure a consistently safe and reliable cryopreservation solution.
Ben Fryer, CEO of Pluristyx, stated, “Our goal as an organization is to be a problem-solving partner for our customers, and one of the long-standing challenges for cell therapy developers has been the availability of high-performing, scalable, and cost-effective cryopreservation formulations. The launch of PluriFreeze™ represents a significant step forward in our commitment to providing comprehensive solutions for iPSCs with an entirely synthetic and AOF workflow. The strong compatibility of PluriFreze™ with our PluriBank, clinical-grade, pre-edited iPSCs, allows us to offer an integrated approach to our customers. Furthermore, the ability to complement PluriFreeze™ with our existing cryo-development services enables us to optimize our customers’ entire cryopreservation workflow with an eye toward the commercialization and the clinic. We invite our customers and collaborators to test PluriFreeze™ today to simplify their cryopreservation workflows.”
About Pluristyx
Pluristyx, through its panCELLa Platform, offers a portfolio of unique iPSC-based technologies, proprietary genetic engineering, and related tool-products and services to provide end-to-end client support throughout the products’ lifecycle. Pluristyx is fast becoming the leading provider of gene-edited iPSC and cell therapy solutions, accelerating customers’ path to clinic, and providing the best and fastest route to commercialization for cell-based therapeutic products. For more information on Pluristyx, please visit www.pluristyx.com.